BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 33914699)

  • 1. Apoplexy of microprolactinomas during pregnancy: report of five cases and review of the literature.
    Kuhn E; Weinreich AA; Biermasz NR; Jorgensen JOL; Chanson P
    Eur J Endocrinol; 2021 May; 185(1):99-108. PubMed ID: 33914699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pituitary apoplexy in a pregnant woman with cystic microprolactinoma].
    Querol Ripoll R; Cámara Gómez R; Del Olmo García M; Simal Julián JA; Merino Torres JF
    Endocrinol Nutr; 2015 Apr; 62(4):200-2. PubMed ID: 25732323
    [No Abstract]   [Full Text] [Related]  

  • 3. Transsphenoidal surgery for a life-threatening prolactinoma apoplexy during pregnancy.
    Witek P; Zieliński G; Maksymowicz M; Zgliczyński W
    Neuro Endocrinol Lett; 2012; 33(5):483-8. PubMed ID: 23090264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolactinomas and pregnancy.
    Bronstein MD
    Pituitary; 2005; 8(1):31-8. PubMed ID: 16411066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolactinoma and pregnancy: From the wish of conception to lactation.
    Maiter D
    Ann Endocrinol (Paris); 2016 Jun; 77(2):128-34. PubMed ID: 27130071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pituitary apoplexy of a giant prolactinoma during pregnancy.
    Khaldi S; Saad G; Elfekih H; Ben Abdelkrim A; Ach T; Kacem M; Chaieb M; Maaroufi A; Hasni Y; Ach K
    Gynecol Endocrinol; 2021 Sep; 37(9):863-866. PubMed ID: 34124989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pituitary apoplexy associated with cabergoline therapy.
    Chng E; Dalan R
    J Clin Neurosci; 2013 Dec; 20(12):1637-43. PubMed ID: 24113159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolactinoma surgery.
    Jan M; Dufour H; Brue T; Jaquet P
    Ann Endocrinol (Paris); 2007 Jun; 68(2-3):118-9. PubMed ID: 17512893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolactinomas in pregnancy: considerations before conception and during pregnancy.
    Glezer A; Bronstein MD
    Pituitary; 2020 Feb; 23(1):65-69. PubMed ID: 31792668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current approach to treatments for prolactinomas.
    Tirosh A; Shimon I
    Minerva Endocrinol; 2016 Sep; 41(3):316-23. PubMed ID: 26399371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency of pituitary tumor apoplexy during treatment of prolactinomas with dopamine agonists: a systematic review.
    Carija R; Vucina D
    CNS Neurol Disord Drug Targets; 2012 Dec; 11(8):1012-4. PubMed ID: 23244423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of prolactinomas during pregnancy.
    Witek P; Zieliński G
    Minerva Endocrinol; 2013 Dec; 38(4):351-63. PubMed ID: 24285103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolactinoma and pregnancy - a series of cases including pituitary apoplexy.
    Galvão A; Gonçalves D; Moreira M; Inocêncio G; Silva C; Braga J
    J Obstet Gynaecol; 2017 Apr; 37(3):284-287. PubMed ID: 27866462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Prolactinoma.
    Inder WJ; Jang C
    Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolactin, prolactin disorders, and dopamine agonists during pregnancy.
    Levin G; Rottenstreich A
    Hormones (Athens); 2019 Jun; 18(2):137-139. PubMed ID: 30341577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gestational pituitary apoplexy: Case series and review of the literature.
    Jemel M; Kandara H; Riahi M; Gharbi R; Nagi S; Kamoun I
    J Gynecol Obstet Hum Reprod; 2019 Dec; 48(10):873-881. PubMed ID: 31059861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis and drug therapy of prolactinoma.
    Ciccarelli E; Camanni F
    Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of prolactinomas: a survey of physicians from the Middle East and North Africa.
    Beshyah SA; Sherif IH; Chentli F; Hamrahian A; Khalil AB; Raef H; El-Fikki M; Jambart S
    Pituitary; 2017 Apr; 20(2):231-240. PubMed ID: 27783196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
    Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
    Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SURGICAL OUTCOMES OF PROLACTINOMAS IN RECENT ERA: RESULTS OF A HETEROGENOUS GROUP.
    Donegan D; Atkinson JL; Jentoft M; Natt N; Nippoldt TB; Erickson B; Meyer F; Erickson D
    Endocr Pract; 2017 Jan; 23(1):37-45. PubMed ID: 27682355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.